Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review)
- Authors:
- Jorge Augusto Borin Scutti
-
Affiliations: Immunotherapy Platform, Immunology Department, MD Anderson Cancer Center, Houston, TX 77054, USA - Published online on: February 23, 2018 https://doi.org/10.3892/ijo.2018.4283
- Pages: 1041-1056
-
Copyright: © Scutti . This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Mukherjee S: The Emperor of All Maladies. Scribner publisher; 2010 | |
National Cancer Institute (NCI): https://www.cancer.gov. | |
Willers H, Azzoli CG, Santivasi WL and Xia F: Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer. Cancer J. 19:200–207. 2013. View Article : Google Scholar : PubMed/NCBI | |
Barker HE, Paget JT, Khan AA and Harrington KJ: The tumour microenvironment after radiotherapy: Mechanisms of resistance and recurrence. Nat Rev Cancer. 15:409–425. 2015. View Article : Google Scholar : PubMed/NCBI | |
Alfarouk KO, Stock CM, Taylor S, Walsh M, Muddathir AK, Verduzco D, Bashir AH, Mohammed OY, Elhassan GO, Harguindey S, et al: Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int. 15:712015. View Article : Google Scholar : PubMed/NCBI | |
Raguz S and Yagüe E: Resistance to chemotherapy: New treatments and novel insights into an old problem. Br J Cancer. 99:387–391. 2008. View Article : Google Scholar : PubMed/NCBI | |
Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H and Haga N: Molecular targeting therapy of cancer: Drug resistance, apoptosis and survival signal. Cancer Sci. 94:15–21. 2003. View Article : Google Scholar : PubMed/NCBI | |
Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI | |
Hanahan D and Weinberg RA: The hallmarks of cancer: The next generation. Cell. 5:646–674. 2011. View Article : Google Scholar | |
Lee S and Margolin K: Cytokines in cancer immunotherapy. Cancers (Basel). 3:3856–3893. 2011. View Article : Google Scholar | |
Levitzki A and Klein S: Signal transduction therapy of cancer. Mol Aspects Med. 31:287–329. 2010. View Article : Google Scholar : PubMed/NCBI | |
Lawler SE, Speranza MC, Cho CF and Chiocca EA: Oncolytic viruses in cancer treatment: A Review. JAMA Oncol. 3:841–849. 2017. View Article : Google Scholar | |
Rajabi M and Mousa SA: The role of angiogenesis in cancer treatment. Biomedicines. 5:E342017. View Article : Google Scholar : PubMed/NCBI | |
Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ and Schreiber RD: IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 410:1107–1111. 2001. View Article : Google Scholar : PubMed/NCBI | |
Dunn GP, Bruce AT, Ikeda H, Old LJ and Schreiber RD: Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol. 3:991–998. 2002. View Article : Google Scholar : PubMed/NCBI | |
Mittal D, Gubin MM, Schreiber RD and Smyth MJ: New insights into cancer immunoediting and its three component phases - elimination, equilibrium and escape. Curr Opin Immunol. 27:16–25. 2014. View Article : Google Scholar : PubMed/NCBI | |
Vesely MD and Schreiber RD: Cancer immunoediting: Antigens, mechanisms, and implications to cancer immunotherapy. Ann NY Acad Sci. 1284:1–5. 2013. View Article : Google Scholar : PubMed/NCBI | |
Dunn GP, Old LJ and Schreiber RD: The three Es of cancer immunoediting. Annu Rev Immunol. 22:329–360. 2004. View Article : Google Scholar : PubMed/NCBI | |
Dunn GP, Koebel CM and Schreiber RD: Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 6:836–848. 2006. View Article : Google Scholar : PubMed/NCBI | |
Baxevanis CN, Perez SA and Papamichail M: Cancer immunotherapy. Crit Rev Clin Lab Sci. 46:167–189. 2009. View Article : Google Scholar : PubMed/NCBI | |
Cancer Research Institute (CRI): https://www.cancerresearch.org. | |
Immunotherapy MD Anderson Cancer Center (MDACC): https://www.mdanderson.org/treatment-options/immunotherapy.html. | |
Sathyanarayanan V and Neelapu SS: Cancer immunotherapy: Strategies for personalization and combinatorial approaches. Mol Oncol. 9:2043–2053. 2015. View Article : Google Scholar : PubMed/NCBI | |
Farkona S, Diamandis EP and Blasutig IM: Cancer immunotherapy: The beginning of the end of cancer. BMC Med. 14:732016. View Article : Google Scholar | |
Newick K, O'Brien S, Moon E and Albelda SM: CAR T cell therapy for solid tumors. Annu Rev Med. 68:139–152. 2017. View Article : Google Scholar | |
Romero D: Immunotherapy: A CAR T-cell recipe for success. Nat Rev Clin Oncol. 14:3302017. View Article : Google Scholar : PubMed/NCBI | |
Couzin-Frankel J: Breakthrough of the year 2013. Cancer immunotherapy. Science. 342:1432–1433. 2013. View Article : Google Scholar : PubMed/NCBI | |
Buchbinder EI and Desai A: CTLA-4 and PD-1 Pathways: Similarities, differences, and implications of their inhibition. Am J Clin Oncol. 39:98–106. 2016. View Article : Google Scholar : | |
Leach DR, Krummel MF and Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science. 271:1734–1736. 1996. View Article : Google Scholar : PubMed/NCBI | |
Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA and Sharpe AH: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 3:541–547. 1995. View Article : Google Scholar : PubMed/NCBI | |
Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H and Mak TW: Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 270:985–988. 1995. View Article : Google Scholar : PubMed/NCBI | |
Curran MA, Montalvo W, Yagita H and Allison JP: PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA. 107:4275–4280. 2010. View Article : Google Scholar : PubMed/NCBI | |
Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M and Korman AJ: Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 1:32–42. 2013. View Article : Google Scholar | |
Thomas LJ, He LZ, Marsh H and Keler T: Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity. Oncoimmunology. 3:e272552014. View Article : Google Scholar : PubMed/NCBI | |
He LZ, Prostak N, Thomas LJ, Vitale L, Weidlick J, Crocker A, Pilsmaker CD, Round SM, Tutt A, Glennie MJ, et al: Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. J Immunol. 191:4174–4183. 2013. View Article : Google Scholar : PubMed/NCBI | |
Emens LA, Butterfield LH, Hodi FS Jr, Marincola FM and Kaufman HL: Cancer immunotherapy trials: Leading a paradigm shift in drug development. J Immunother Cancer. 4:422016. View Article : Google Scholar : PubMed/NCBI | |
Bartkowiak T and Curran MA: 4-1BB agonists: Multi-potent potentiators of tumor immunity. Front Oncol. 5:1172015. View Article : Google Scholar : PubMed/NCBI | |
Chester C, Ambulkar S and Kohrt HE: 4-1BB agonism: Adding the accelerator to cancer immunotherapy. Cancer Immunol Immunother. 65:1243–1248. 2016. View Article : Google Scholar : PubMed/NCBI | |
Bartkowiak T, Singh S, Yang G, Galvan G, Haria D, Ai M, Allison JP, Sastry KJ and Curran MA: Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc Natl Acad Sci USA. 112:E5290–E5299. 2015. View Article : Google Scholar : PubMed/NCBI | |
Knee DA, Hewes B and Brogdon JL: Rationale for anti-GITR cancer immunotherapy. Eur J Cancer. 67:1–10. 2016. View Article : Google Scholar : PubMed/NCBI | |
Linch SN, McNamara MJ and Redmond WL: OX40 agonists and combination immunotherapy: Putting the pedal to the metal. Front Oncol. 5:342015. View Article : Google Scholar : PubMed/NCBI | |
Lipson EJ and Drake CG: Ipilimumab: An anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 17:6958–6962. 2011. View Article : Google Scholar : PubMed/NCBI | |
Hellman MD, Ott PA, Zugazagoitia J, Ready NE, Hann CL and De Braud FG: Nivolumab (Nivo) + Ipilimumab (Ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from checkmate 032. J Clin Oncol. 35:85032017. | |
Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F, Han B, Ganea DE, Von Pawel J, Vladimirov V, et al: Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J Clin Oncol. 35:3449–3457. 2017. View Article : Google Scholar : PubMed/NCBI | |
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260). NCT: 02553642. Available at http://ClinicalTrial.govurisimpleClinical Trial.gov. | |
Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy (NABUCCO. NCT:03387761). Available at http://ClinicalTrial.govurisimpleClinicalTrial.gov. | |
Ipilimumab + Androgen Deprivation Therapy in Prostate Cancer. NCT:01377389. Available at http://ClinicalTrial.govurisimpleClinicalTrial.gov. | |
Reddy SM, Amaria RN and Spencer CN: Neoadjuvant nivolumab versus combination ipilimumab and nivolumab followed by adjuvant nivolumab in patients with resectable stage III and oligometastatic stage IV melanoma: Preliminary findings. Presented at: 32nd SITC Annual Meeting; Nov 8–12, 2017; National Harbor, MD. Abstract O15. | |
Mazza C, Escudier B and Albiges L: Nivolumab in renal cell carcinoma: Latest evidence and clinical potential. Ther Adv Med Oncol. 9:171–181. 2017. View Article : Google Scholar : PubMed/NCBI | |
Sorensen SF, Zhou W, Dolled-Filhart M, Georgsen JB, Wang Z, Emancipator K, Wu D, Busch-Sørensen M, Meldgaard P and Hager H: PD-L1 expression and survival among patients with advanced non-small cell lung cancer treated with chemotherapy. Transl Oncol. 9:64–69. 2016. View Article : Google Scholar : PubMed/NCBI | |
Sheng Z, Zhu X, Sun Y and Zhang Y: The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer. Oncotarget. 8:57826–57835. 2017. View Article : Google Scholar : PubMed/NCBI | |
Byun DJ, Wolchok JD, Rosenberg LM and Girotra M: Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 13:195–207. 2017. View Article : Google Scholar : PubMed/NCBI | |
Immunotherapy strategies. Extracted from Society for Immunotherapy for Cancer. https://www.sitcancer.org/home. | |
Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, de Chaisemartin L, Ouakrim H, Becht E, Alifano M, et al: Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 74:705–715. 2014. View Article : Google Scholar | |
Scott DW, Chan FC, Hong F, Rogic S, Tan KL, Meissner B, Ben-Neriah S, Boyle M, Kridel R, Telenius A, et al: Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol. 31:692–700. 2013. View Article : Google Scholar | |
Muris JJ, Meijer CJ, Cillessen SA, Vos W, Kummer JA, Bladergroen BA, Bogman MJ, MacKenzie MA, Jiwa NM, Siegenbeek van Heukelom LH, et al: Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia. 18:589–596. 2004. View Article : Google Scholar : PubMed/NCBI | |
Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H and Ohtani H: Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: Clinicopathologic demonstration of antitumor immunity. Cancer Res. 61:5132–5136. 2001.PubMed/NCBI | |
Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean MC, Riquet M, Crozet L, Ouakrim H, Goc J, Cazes A, et al: Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: Influence of tumor origin. Clin Cancer Res. 19:4079–4091. 2013. View Article : Google Scholar : PubMed/NCBI | |
Mori M, Ohtani H, Naito Y, Sagawa M, Sato M, Fujimura S and Nagura H: Infiltration of CD8+ T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis. Tohoku J Exp Med. 191:113–118. 2000. View Article : Google Scholar : PubMed/NCBI | |
Sharpe AH: Introduction to checkpoint inhibitors and cancer immunotherapy. Immunol Rev. 276:5–8. 2017. View Article : Google Scholar : PubMed/NCBI | |
Chongsathidkiet P, Farber SH, Woroniecka K, Elsamadicy AA, Cui X and Fecci P: IMST-11: Downregulation of sphin-gosine-1-phosphate receptor type 1 mediates bone marrow T-cell sequestration in patients and mice with glioblastoma. Neuro Oncol. 18(Suppl 6): vi882016. View Article : Google Scholar | |
Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, Yu D, Kanojia D, Pituch KC, Qiao J, Pytel P, et al: CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells. Cancer Res. 76:5671–5682. 2016. View Article : Google Scholar : PubMed/NCBI | |
Mitsuka K, Kawataki T, Satoh E, Asahara T, Horikoshi T and Kinouchi H: Expression of indoleamine 2.3-dioxygenase and correlation with pathological malignancy in gliomas. Neurosurgery. 72:1031–1039. 2013. View Article : Google Scholar | |
Komori T: The 2016 WHO classification of tumors of the central nervous system: The major points of revision. Neurol Med Chir (Tokyo). 57:301–311. 2017. View Article : Google Scholar | |
Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, et al: Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6:827–837. 2016. View Article : Google Scholar : PubMed/NCBI | |
Freeman CR and Farmer JP: Pediatric brain stem gliomas: A review. Int J Radiat Oncol Biol Phys. 40:265–271. 1998. View Article : Google Scholar : PubMed/NCBI | |
Rubin G, Michowitz S, Horev G, Herscovici Z, Cohen IJ, Shuper A and Rappaport ZH: Pediatric brain stem gliomas: An update. Childs Nerv Syst. 14:167–173. 1998. View Article : Google Scholar : PubMed/NCBI | |
Epstein FJ and Farmer JP: Brain-stem glioma growth patterns. J Neurosurg. 78:408–412. 1993. View Article : Google Scholar : PubMed/NCBI | |
Epstein F and Constantini S: Practical decisions in the treatment of pediatric brain stem tumors. Pediatr Neurosurg. 24:24–34. 1996. View Article : Google Scholar : PubMed/NCBI | |
Robertson PL, Allen JC, Abbott IR, Miller DC, Fidel J and Epstein FJ: Cervicomedullary tumors in children: A distinct subset of brainstem gliomas. Neurology. 44:1798–1803. 1994. View Article : Google Scholar : PubMed/NCBI | |
Pollack IF, Hoffman HJ, Humphreys RP and Becker L: The long-term outcome after surgical treatment of dorsally exophytic brain-stem gliomas. J Neurosurg. 78:859–863. 1993. View Article : Google Scholar : PubMed/NCBI | |
Fisher PG, Breiter SN, Carson BS, Wharam MD, Williams JA, Weingart JD, Foer DR, Goldthwaite PT, Tihan T and Burger PC: A clinicopathologic reappraisal of brain stem tumor classification. Identification of pilocystic astrocytoma and fibrillary astrocytoma as distinct entities. Cancer. 89:1569–1576. 2000. View Article : Google Scholar : PubMed/NCBI | |
Warren K: DIPG: Poised for progress. Front Oncol. 2:2052012. | |
Vanan MI and Eisenstat DD: DIPG in children - what can we learn from the past. Front Oncol. 5:2372015. View Article : Google Scholar | |
Ridler C: Neuro-oncology: New therapeutic targets for diffuse intrinsic pontine glioma. Nat Rev Neurol. 13:1962017. View Article : Google Scholar : PubMed/NCBI | |
Schroeder KM, Hoeman CM and Becher OJ: Children are not just little adults: Recent advances in understanding of diffuse intrinsic pontine glioma biology. Pediatr Res. 75:205–209. 2014. View Article : Google Scholar | |
Disis ML: Immune regulation of cancer. J Clin Oncol. 28:4531–4538. 2010. View Article : Google Scholar : PubMed/NCBI | |
Lewis PW, Müller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, Garcia BA, Muir TW, Becher OJ and Allis CD: Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science. 340:857–861. 2013. View Article : Google Scholar : PubMed/NCBI | |
Zhang L, Chen LH, Wan H, Yang R, Wang Z, Feng J, Yang S, Jones S, Wang S, Zhou W, et al: Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nat Genet. 46:726–730. 2014. View Article : Google Scholar : PubMed/NCBI | |
Gwak HS and Park HJ: Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG). Crit Rev Oncol Hematol. 120:111–119. 2017. View Article : Google Scholar : PubMed/NCBI | |
Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI | |
Wang ZJ, Rao L, Bhambhani K, Miller K, Poulik J, Altinok D and Sood S: Diffuse intrinsic pontine glioma biopsy: A single institution experience. Pediatr Blood Cancer. 62:163–165. 2015. View Article : Google Scholar | |
Anderson RC, Kennedy B, Yanes CL, Garvin J, Needle M, Canoll P, Feldstein NA and Bruce JN: Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children. J Neurosurg Pediatr. 11:289–295. 2013. View Article : Google Scholar | |
Monje M, Mitra SS, Freret ME, Raveh TB, Kim J, Masek M, Attema JL, Li G, Haddix T, Edwards MS, et al: Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci USA. 108:4453–4458. 2011. View Article : Google Scholar : PubMed/NCBI | |
Morales La, Madrid A, Hashizume R and Kieran MW: Future clinical trials in DIPG: Bringing epigenetics to the clinic. Front Oncol. 5:1482015. | |
Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, Quist MJ, Davis LE, Huang EC, Woo PJ, et al: Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med. 21:555–559. 2015. View Article : Google Scholar : PubMed/NCBI | |
Murakami T, Sato A, Chun NA, Hara M, Naito Y, Kobayashi Y, Kano Y, Ohtsuki M, Furukawa Y and Kobayashi E: Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma. J Invest Dermatol. 128:1506–1516. 2008. View Article : Google Scholar : PubMed/NCBI | |
Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C, Keiser N, Santaniello F and Tomasi TB: Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol. 165:7017–7024. 2000. View Article : Google Scholar : PubMed/NCBI | |
Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, et al: Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 65:6321–6329. 2005. View Article : Google Scholar : PubMed/NCBI | |
Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM and Adema GJ: HDAC inhibitors and immunotherapy; a double edged sword. Oncotarget. 5:6558–6572. 2014. View Article : Google Scholar : PubMed/NCBI | |
Schläger C, Körner H, Krueger M, Vidoli S, Haberl M, Mielke D, Brylla E, Issekutz T, Cabañas C, Nelson PJ, et al: Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid. Nature. 530:349–353. 2016. View Article : Google Scholar : PubMed/NCBI | |
Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS, et al: Structural and functional features of central nervous system lymphatic vessels. Nature. 523:337–341. 2015. View Article : Google Scholar : PubMed/NCBI | |
Aspelund A, Antila S, Proulx ST, Karlsen TV, Karaman S, Detmar M, Wiig H and Alitalo K: A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med. 212:991–999. 2015. View Article : Google Scholar : PubMed/NCBI | |
Sampson JH, Maus MV and June CH: Immunotherapy for brain tumors. J Clin Oncol. 35:2450–2456. 2017. View Article : Google Scholar : PubMed/NCBI | |
Frazier JL, Lee J, Thomale UW, Noggle JC, Cohen KJ and Jallo GI: Treatment of diffuse intrinsic brainstem gliomas: Failed approaches and future strategies. J Neurosurg Pediatr. 3:259–269. 2009. View Article : Google Scholar : PubMed/NCBI | |
Ye Z and Qian Q, Jin H and Qian Q: Cancer vaccine: Learning lessons from immune checkpoint inhibitors. J Cancer. 9:263–268. 2018. View Article : Google Scholar : PubMed/NCBI | |
Mellman I, Coukos G and Dranoff G: Cancer immunotherapy comes of age. Nature. 480:480–489. 2011. View Article : Google Scholar : PubMed/NCBI | |
Wainwright DA, Nigam P, Thaci B, Dey M and Lesniak MS: Recent developments on immunotherapy for brain cancer. Expert Opin Emerg Drugs. 17:181–202. 2012. View Article : Google Scholar : PubMed/NCBI | |
Sonabend AM, Ogden AT, Maier LM, Anderson DE, Canoll P, Bruce JN and Anderson RC: Medulloblasoma: Challenges for effective immunotherapy. J Neurooncol. 108:1–10. 2012. View Article : Google Scholar | |
Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C and Wölfel T: The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA. 102:16013–16018. 2005. View Article : Google Scholar : PubMed/NCBI | |
Zhou J, Dudley ME, Rosenberg SA and Robbins PF: Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother. 28:53–62. 2005. View Article : Google Scholar | |
Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, Kvistborg P, Maccalli C, Maecker HT, Page DB, et al: Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer. 4:32016. View Article : Google Scholar : PubMed/NCBI | |
Bobisse S, Foukas PG, Coukos G and Harari A: Neoantigen-based cancer immunotherapy. Ann Transl Med. 4:2622016. View Article : Google Scholar : PubMed/NCBI | |
Wang RF and Wang HY: Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res. 27:11–37. 2017. View Article : Google Scholar : | |
Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B and Allison JP: Epitope landscape in breast and colorectal cancer. Cancer Res. 68:889–892. 2008. View Article : Google Scholar : PubMed/NCBI | |
Joyce JA and Fearon DT: T cell exclusion, immune privilege, and the tumor microenvironment. Science. 348:74–80. 2015. View Article : Google Scholar : PubMed/NCBI | |
Schumacher TN and Schreiber RD: Neoantigens in cancer immunotherapy. Science. 348:69–74. 2015. View Article : Google Scholar : PubMed/NCBI | |
Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Potter DM, Connelly AK, Dibridge SA, Whiteside TL and Okada H: Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol. 32:2050–2058. 2014. View Article : Google Scholar : PubMed/NCBI | |
Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, et al: Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. Neuro Oncol. 18:1157–1168. 2016. View Article : Google Scholar : PubMed/NCBI | |
Chheda ZS, Kohanbash G, Okada K, Jahan N, Sidney J, Pecoraro M, Yang X, Carrera DA, Downey KM, Shrivastav S, et al: Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. J Exp Med. 215:141–157. 2018. View Article : Google Scholar | |
Ochs K, Ott M, Bunse T, Sahm F, Bunse L, Deumelandt K, Sonner JK, Keil M, von Deimling A, Wick W, et al: K27M-mutant histone-3 as a novel target for glioma immunotherapy. Oncoimmunology. 6:e13283402017. View Article : Google Scholar : PubMed/NCBI | |
Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, et al: Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 7:264–276. 2017. View Article : Google Scholar : | |
Riaz N, Morris L, Havel JJ, Makarov V, Desrichard A and Chan TA: The role of neoantigens in response to immune checkpoint blockade. Int Immunol. 28:411–419. 2016. View Article : Google Scholar : PubMed/NCBI | |
Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, et al: Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 515:577–581. 2014. View Article : Google Scholar : PubMed/NCBI | |
Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 547:217–221. 2017. View Article : Google Scholar : PubMed/NCBI | |
Zhou Z, Luther N, Ibrahim GM, Hawkins C, Vibhakar R, Handler MH and Souweidane MM: B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. J Neurooncol. 111:257–264. 2013. View Article : Google Scholar | |
Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P and Allison JP: B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA. 104:19458–19463. 2007. View Article : Google Scholar : PubMed/NCBI | |
Lee H, Kim JH, Yang SY, Kong J, Oh M, Jeong DH, Chung JI, Bae KB, Shin JY, Hong KH, et al: Peripheral blood gene expression of B7 and CD28 family members associated with tumor progression and microscopic lymphovascular invasion in colon cancer patients. J Cancer Res Clin Oncol. 136:1445–1452. 2010. View Article : Google Scholar : PubMed/NCBI | |
Yamato I, Sho M, Nomi T, Akahori T, Shimada K, Hotta K, Kanehiro H, Konishi N, Yagita H and Nakajima Y: Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer. 101:1709–1716. 2009. View Article : Google Scholar : PubMed/NCBI | |
Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, et al: Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 14:5150–5157. 2008. View Article : Google Scholar : PubMed/NCBI | |
Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, Thaler HT, Arul M, Slovin SF, Wei J, et al: Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol. 23:1104–1112. 2010. View Article : Google Scholar : PubMed/NCBI | |
Boorjian SA, Sheinin Y, Crispen PL, Farmer SA, Lohse CM, Kuntz SM, Leibovich BC, Kwon ED and Frank I: T-cell coregulatory molecule expression in urothelial cell carcinoma: Clinicopathologic correlations and association with survival. Clin Cancer Res. 14:4800–4808. 2008. View Article : Google Scholar : PubMed/NCBI | |
Griesinger AM, Birks DK, Donson AM, Amani V, Hoffman LM, Waziri A, Wang M, Handler MH and Foreman NK: Characterization of distinct immunophenotypes across pediatric brain tumor types. J Immunol. 191:4880–4888. 2013. View Article : Google Scholar : PubMed/NCBI | |
Liu D, Song L, Brawley VS, Robison N, Wei J, Gao X, Tian G, Margol A, Ahmed N, Asgharzadeh S, et al: Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells. Clin Immunol. 149:55–64. 2013. View Article : Google Scholar : PubMed/NCBI | |
Ahmed N, Ratnayake M, Savoldo B, Perlaky L, Dotti G, Wels WS, Bhattacharjee MB, Gilbertson RJ, Shine HD, Weiss HL, et al: Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 67:5957–5964. 2007. View Article : Google Scholar : PubMed/NCBI | |
Hussain SF, Yang D, Suki D, Aldape K, Grimm E and Heimberger AB: The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol. 8:261–279. 2006. View Article : Google Scholar : PubMed/NCBI | |
Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, Durham N, Meyer C, Harris TJ, Albesiano E, et al: Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 86:343–349. 2013. View Article : Google Scholar : PubMed/NCBI | |
Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD and Sampson JH: Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res. 13:2158–2167. 2007. View Article : Google Scholar : PubMed/NCBI | |
Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wöhrer A, Dieckmann K, Filipits M, Brandstetter A, Weller M, et al: Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol. 17:1064–1075. 2015. View Article : Google Scholar : | |
Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM and van Hall T: The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol. 39:44–51. 2016. View Article : Google Scholar : PubMed/NCBI | |
Warren K, Bent R, Wolters PL, Prager A, Hanson R, Packer R, Shih J and Camphausen K: A phase 2 study of pegylated interferon α-2b (PEG-Intron(®)) in children with diffuse intrinsic pontine glioma. Cancer. 118:3607–3613. 2012. View Article : Google Scholar | |
Greil R, Hutterer E, Hartmann TN and Pleyer L: Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation. Cell Commun Signal. 15:52017. View Article : Google Scholar : PubMed/NCBI | |
Khanna R: Tumour surveillance: Missing peptides and MHC molecules. Immunol Cell Biol. 76:20–26. 1998. View Article : Google Scholar : PubMed/NCBI | |
Campoli M and Ferrone S: HLA antigen changes in malignant cells: Epigenetic mechanisms and biologic significance. Oncogene. 27:5869–5885. 2008. View Article : Google Scholar : PubMed/NCBI | |
Zhang HG, Wang J, Yang X, Hsu HC and Mountz JD: Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene. 23:2009–2015. 2004. View Article : Google Scholar : PubMed/NCBI | |
Ozören N and El-Deiry WS: Cell surface Death Receptor signaling in normal and cancer cells. Semin Cancer Biol. 13:135–147. 2003. View Article : Google Scholar : PubMed/NCBI | |
Wu Y, Chen M, Wu P, Chen C, Xu ZP and Gu W: Increased PD-L1 expression in breast and colon cancer stem cells. Clin Exp Pharmacol Physiol. 44:602–604. 2017. View Article : Google Scholar : PubMed/NCBI | |
Zitvogel L and Kroemer G: Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology. 1:1223–1225. 2012. View Article : Google Scholar : PubMed/NCBI | |
He J, Hu Y, Hu M and Li B: Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep. 5:131102015. View Article : Google Scholar : PubMed/NCBI | |
Dolan DE and Gupta S: PD-1 pathway inhibitors: Changing the landscape of cancer immunotherapy. Cancer Contr. 21:231–237. 2014. View Article : Google Scholar | |
Picarda E, Ohaegbulam KC and Zang X: Molecular pathways: Targeting B7-H3 (CD276) for human cancer immunotherapy. Clin Cancer Res. 22:3425–3431. 2016. View Article : Google Scholar : PubMed/NCBI | |
Jiang B, Liu F, Liu Z, Zhang T and Hua D: B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway. Tumour Biol. 37:9465–9472. 2016. View Article : Google Scholar : PubMed/NCBI | |
Silva TG, Crispim JC, Miranda FA, Hassumi MK, de Mello JM, Simões RT, Souto F, Soares EG, Donadi EA and Soares CP: Expression of the nonclassical HLA-G and HLA-E molecules in laryngeal lesions as biomarkers of tumor invasiveness. Histol Histopathol. 26:1487–1497. 2011.PubMed/NCBI | |
Zang X, Loke P, Kim J, Murphy K, Waitz R and Allison JP: B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci USA. 100:10388–10392. 2003. View Article : Google Scholar : PubMed/NCBI | |
Mahoney KM, Rennert PD and Freeman GJ: Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 14:561–584. 2015. View Article : Google Scholar : PubMed/NCBI | |
Hou J, Greten TF and Xia Q: Immunosuppressive cell death in cancer. Nat Rev Immunol. 17:4012017. View Article : Google Scholar : PubMed/NCBI | |
Joshi BH, Plautz GE and Puri RK: Interleukin-13 receptor alpha chain: A novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res. 60:1168–1172. 2000.PubMed/NCBI | |
Okano F, Storkus WJ, Chambers WH, Pollack IF and Okada H: Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res. 8:2851–2855. 2002.PubMed/NCBI | |
Tsuda N, Nonaka Y, Shichijo S, Yamada A, Ito M, Maeda Y, Harada M, Kamura T and Itoh K: UDP-Gal: betaGlcNAc beta1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumour. Br J Cancer. 87:1006–1012. 2002. View Article : Google Scholar : PubMed/NCBI | |
Schmitz M, Temme A, Senner V, Ebner R, Schwind S, Stevanovic S, Wehner R, Schackert G, Schackert HK, Fussel M, et al: Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer. 96:1293–1301. 2007. View Article : Google Scholar : PubMed/NCBI | |
Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R and Aldape K: Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 11:1462–1466. 2005. View Article : Google Scholar : PubMed/NCBI | |
Ueda R, Iizuka Y, Yoshida K, Kawase T, Kawakami Y and Toda M: Identification of a human glioma antigen, SOX6, recognized by patients' sera. Oncogene. 23:1420–1427. 2004. View Article : Google Scholar | |
Pallasch CP, Struss AK, Munnia A, König J, Steudel WI, Fischer U and Meese E: Autoantibodies against GLEA2 and PHF3 in glioblastoma: Tumor-associated autoantibodies correlated with prolonged survival. Int J Cancer. 117:456–459. 2005. View Article : Google Scholar : PubMed/NCBI | |
Arnon TI, Markel G and Mandelboim O: Tumor and viral recognition by natural killer cells receptors. Semin Cancer Biol. 16:348–358. 2006. View Article : Google Scholar : PubMed/NCBI | |
Wu A, Wiesner S, Xiao J, Ericson K, Chen W, Hall WA, Low WC and Ohlfest JR: Expression of MHC I and NK ligands on human CD133+ glioma cells: Possible targets of immunotherapy. J Neurooncol. 83:121–131. 2007. View Article : Google Scholar | |
Eisele G, Wischhusen J, Mittelbronn M, Meyermann R, Waldhauer I, Steinle A, Weller M and Friese MA: TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain. 129:2416–2425. 2006. View Article : Google Scholar : PubMed/NCBI | |
Groh V, Bahram S, Bauer S, Herman A, Beauchamp M and Spies T: Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA. 93:12445–12450. 1996. View Article : Google Scholar : PubMed/NCBI | |
Hatano M, Eguchi J, Tatsumi T, Kuwashima N, Dusak JE, Kinch MS, Pollack IF, Hamilton RL, Storkus WJ and Okada H: EphA2 as a glioma-associated antigen: A novel target for glioma vaccines. Neoplasia. 7:717–722. 2005. View Article : Google Scholar : PubMed/NCBI | |
Zhang JG, Eguchi J, Kruse CA, Gomez GG, Fakhrai H, Schroter S, Ma W, Hoa N, Minev B, Delgado C, et al: Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res. 13:566–575. 2007. View Article : Google Scholar : PubMed/NCBI | |
Jin M, Komohara Y, Shichijo S, Harada M, Yamanaka R, Miyamoto S, Nikawa J, Itoh K and Yamada A: Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients. Oncol Rep. 19:1277–1283. 2008.PubMed/NCBI | |
Liu G, Yu JS, Zeng G, Yin D, Xie D, Black KL and Ying H: AIM-2: A novel tumor antigen is expressed and presented by human glioma cells. J Immunother. 27:220–226. 2004. View Article : Google Scholar : PubMed/NCBI | |
Imaizumi T, Kuramoto T, Matsunaga K, Shichijo S, Yutani S, Shigemori M, Oizumi K and Itoh K: Expression of the tumor-rejection antigen SART1 in brain tumors. Int J Cancer. 83:760–764. 1999. View Article : Google Scholar : PubMed/NCBI | |
Murayama K, Kobayashi T, Imaizumi T, Matsunaga K, Kuramoto T, Shigemori M, Shichijo S and Itoh K: Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides. J Immunother. 23:511–518. 2000. View Article : Google Scholar : PubMed/NCBI | |
Liu G, Ying H, Zeng G, Wheeler CJ, Black KL and Yu JS: HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res. 64:4980–4986. 2004. View Article : Google Scholar : PubMed/NCBI | |
Saikali S, Avril T, Collet B, Hamlat A, Bansard JY, Drenou B, Guegan Y and Quillien V: Expression of nine tumour antigens in a series of human glioblastoma multiforme: Interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol. 81:139–148. 2007. View Article : Google Scholar | |
Liu G, Khong HT, Wheeler CJ, Yu JS, Black KL and Ying H: Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma. J Immunother. 26:301–312. 2003. View Article : Google Scholar : PubMed/NCBI | |
Chi DD, Merchant RE, Rand R, Conrad AJ, Garrison D, Turner R, Morton DL and Hoon DS: Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol. 150:2143–2152. 1997.PubMed/NCBI | |
Facoetti A, Nano R, Zelini P, Morbini P, Benericetti E, Ceroni M, Campoli M and Ferrone S: Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res. 11:8304–8311. 2005. View Article : Google Scholar : PubMed/NCBI | |
Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE II, McLendon RE, Mitchell DA, et al: Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 28:4722–4729. 2010. View Article : Google Scholar : PubMed/NCBI | |
Zagzag D, Salnikow K, Chiriboga L, Yee H, Lan L, Ali MA, Garcia R, Demaria S and Newcomb EW: Downregulation of major histocompatibility complex antigens in invading glioma cells: Stealth invasion of the brain. Lab Invest. 85:328–341. 2005. View Article : Google Scholar : PubMed/NCBI | |
Mehling M, Simon P, Mittelbronn M, Meyermann R, Ferrone S, Weller M and Wiendl H: WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: Does it reflect a potential immune escape mechanism. Acta Neuropathol. 114:111–119. 2007. View Article : Google Scholar : PubMed/NCBI | |
Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL and Parsa AT: TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol. 12:7–13. 2010. View Article : Google Scholar : PubMed/NCBI | |
Groh V, Wu J, Yee C and Spies T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 419:734–738. 2002. View Article : Google Scholar : PubMed/NCBI | |
Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I and Fontana A: Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol. 143:3222–3229. 1989.PubMed/NCBI | |
Wrann M, Bodmer S, de Martin R, Siepl C, Hofer-Warbinek R, Frei K, Hofer E and Fontana A: T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO J. 6:1633–1636. 1987.PubMed/NCBI | |
Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Priebe W, et al: Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther. 9:67–78. 2010. View Article : Google Scholar : PubMed/NCBI | |
de Martin R, Haendler B, Hofer-Warbinek R, Gaugitsch H, Wrann M, Schlüsener H, Seifert JM, Bodmer S, Fontana A and Hofer E: Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. EMBO J. 6:3673–3677. 1987.PubMed/NCBI | |
Gide TN, Wilmott JS, Scolyer RA and Long GV: Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin Cancer Res. Nov 10–2017.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI | |
Miao D, De Velasco G, Adeegbe D, Norton C, Martini D, Mullane S, Moreira R, Signoretti S, Wong KK, Choueiri T and Van Allen E: Genomic and neoantigen evolution and resistance to immune checkpoint blockade in metastatic renal cell carcinoma. Cancer Immunol Res. 5:32017. View Article : Google Scholar | |
Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, Sun J, Yang Q, Zhang X and Lu B: TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One. 7:e306762012. View Article : Google Scholar : PubMed/NCBI | |
Yang ZZ, Grote DM, Ziesmer SC, Niki T, Hirashima M, Novak AJ, Witzig TE and Ansell SM: IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest. 122:1271–1282. 2012. View Article : Google Scholar : PubMed/NCBI | |
Andrews LP, Marciscano AE, Drake CG and Vignali DA: LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 276:80–96. 2017. View Article : Google Scholar : PubMed/NCBI | |
Śledzińska A, Menger L, Bergerhoff K, Peggs KS and Quezada SA: Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Mol Oncol. 9:1936–1965. 2015. View Article : Google Scholar : PubMed/NCBI | |
Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, et al: Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA. 107:7875–7880. 2010. View Article : Google Scholar | |
Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, et al: Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72:917–927. 2012. View Article : Google Scholar | |
Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, et al: The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 10:48–57. 2009. View Article : Google Scholar | |
Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel RA, et al: Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 415:536–541. 2002. View Article : Google Scholar : PubMed/NCBI | |
Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK and Anderson AC: Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 207:2187–2194. 2010. View Article : Google Scholar : PubMed/NCBI | |
Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O'Connell S, Ceeraz S, Suriawinata AA, Yan S, Ernstoff MS, et al: VISTA is an immune checkpoint molecule for human T cells. Cancer Res. 74:1924–1932. 2014. View Article : Google Scholar : PubMed/NCBI | |
Beard RE, Abate-Daga D, Rosati SF, Zheng Z, Wunderlich JR, Rosenberg SA and Morgan RA: Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy. Clin Cancer Res. 19:4941–4950. 2013. View Article : Google Scholar : PubMed/NCBI | |
Ryall S, Arnoldo A, Krishnatry R, Mistry M, Khor K, Sheth J, Ling C, Leung S, Zapotocky M, Guerreiro Stucklin A, et al: Multiplex detection of pediatric low-grade glioma signature fusion transcripts and duplications using the NanoString nCounter system. J Neuropathol Exp Neurol. 76:562–570. 2017. View Article : Google Scholar : PubMed/NCBI | |
Chen H, Judkins J, Thomas C, Wu M, Khoury L, Benjamin CG, Pacione D, Golfinos JG, Kumthekar P, Ghamsari F, et al: Mutant IDH1 and seizures in patients with glioma. Neurology. 88:1805–1813. 2017. View Article : Google Scholar : PubMed/NCBI | |
Bassoy EY, Kasahara A, Chiusolo V, Jacquemin G, Boydell E, Zamorano S, Riccadonna C, Pellegatta S, Hulo N, Dutoit V, et al: ER-mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem-like cells. EMBO J. 36:1493–1512. 2017. View Article : Google Scholar : PubMed/NCBI | |
Wells E, Kambhampati M, Damsker JM, Gordish-Dressman H, Yadavilli S, Becher OJ, Gittens J, Stampar M, Packer RJ, Nazarian J, et al: Vamorolone, a dissociative steroidal compound, reduces pro-inflammatory cytokine expression in glioma cells and increases activity and survival in a murine model of cortical tumor. Oncotarget. 8:9366–9374. 2017. View Article : Google Scholar : | |
Rusiecki D, Lach B, Manoranjan B, Fleming A, Ajani O and Singh SK: Progression of atypical extraventricular neurocytoma to anaplastic ganglioglioma. Hum Pathol. 59:125–130. 2017. View Article : Google Scholar | |
Ryall S, Krishnatry R, Arnoldo A, Buczkowicz P, Mistry M, Siddaway R, Ling C, Pajovic S, Yu M, Rubin JB, et al: Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. Acta Neuropathol Commun. 4:932016. View Article : Google Scholar : PubMed/NCBI | |
Lassaletta A, Scheinemann K, Zelcer SM, Hukin J, Wilson BA, Jabado N, Carret AS, Lafay-Cousin L, Larouche V, Hawkins CE, et al: Phase II weekly vinblastine for chemotherapy-naïve children with progressive low-grade glioma: A Canadian Pediatric Brain Tumor Consortium Study. J Clin Oncol. 34:3537–3543. 2016. View Article : Google Scholar : PubMed/NCBI | |
Antonios JP, Soto H, Everson RG, Orpilla J, Moughon D, Shin N, Sedighim S, Yong WH, Li G, Cloughesy TF, et al: PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight. 1:e870592016. View Article : Google Scholar : PubMed/NCBI | |
Nazarian J, Mason GE, Ho CY, Panditharatna E, Kambhampati M, Vezina LG, Packer RJ and Hwang EI: Histological and molecular analysis of a progressive diffuse intrinsic pontine glioma and synchronous metastatic lesions: A case report. Oncotarget. 7:42837–42842. 2016. View Article : Google Scholar : PubMed/NCBI | |
Quail DF, Bowman RL, Akkari L, Quick ML, Schuhmacher AJ, Huse JT, Holland EC, Sutton JC and Joyce JA: The tumor micro-environment underlies acquired resistance to CSF-1R inhibition in gliomas. Science. 352:aad30182016. View Article : Google Scholar | |
Flynn A, Dwight T, Harris J, Benn D, Zhou L, Hogg A, Catchpoole D, James P, Duncan EL, Trainer A, et al: Pheotype: A diagnostic gene-expression assay for the classification of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 101:1034–1043. 2016. View Article : Google Scholar : PubMed/NCBI | |
Nevo I, Woolard K, Cam M, Li A, Webster JD, Kotliarov Y, Kim HS, Ahn S, Walling J, Kotliarova S, et al: Identification of molecular pathways facilitating glioma cell invasion in situ. PLoS One. 9:e1117832014. View Article : Google Scholar : PubMed/NCBI | |
Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V, et al: CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 19:1264–1272. 2013. View Article : Google Scholar : PubMed/NCBI | |
Peruzzi P, Bronisz A, Nowicki MO, Wang Y, Ogawa D, Price R, Nakano I, Kwon CH, Hayes J, Lawler SE, et al: MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells. Neuro Oncol. 15:1212–1224. 2013. View Article : Google Scholar : PubMed/NCBI | |
Kannan K, Inagaki A, Silber J, Gorovets D, Zhang J, Kastenhuber ER, Heguy A, Petrini JH, Chan TA and Huse JT: Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget. 3:1194–1203. 2012. View Article : Google Scholar : PubMed/NCBI | |
Sharpe AH and Freeman GJ: The B7-CD28 superfamily. Nat Rev Immunol. 2:116–126. 2002. View Article : Google Scholar : PubMed/NCBI | |
Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, Greenfield EA and Freeman GJ: Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 170:1257–1266. 2003. View Article : Google Scholar : PubMed/NCBI | |
Francisco LM, Sage PT and Sharpe AH: The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 236:219–242. 2010. View Article : Google Scholar : PubMed/NCBI | |
Nassar AF, Ogura H and Wisnewski AV: Impact of recent innovations in the use of mass cytometry in support of drug development. Drug Discov Today. 20:1169–1175. 2015. View Article : Google Scholar : PubMed/NCBI | |
Bendall SC, Simonds EF, Qiu P, Amir AD, Krutzik PO, Finck R, Bruggner RV, Melamed R, Trejo A, Ornatsky OI, et al: Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science. 332:687–696. 2011. View Article : Google Scholar : PubMed/NCBI | |
Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, Gherardini PF, Prestwood TR, Chabon J, Bendall SC, et al: Systemic immunity is required for effective cancer immunotherapy. Cell. 168:487–502.e15. 2017. View Article : Google Scholar : PubMed/NCBI | |
Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NA, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'er D, et al: Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell. 170:1120–1133.e17. 2017. View Article : Google Scholar : PubMed/NCBI | |
Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, et al: Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol. 15:242–250. 2013. View Article : Google Scholar : | |
Johung TB and Monje M: Diffuse Intrinsic Pontine Glioma: New pathophysiological insights and emerging therapeutics targets. Curr Neuropharmacol. 15:88–97. 2017. View Article : Google Scholar : | |
Bast RC Jr, Croce CM, Hait WN, Hong WK, Kufe DW, Piccart-Gebhart M, Pollock RE, Weichselbaum RR, Wang H and Holland JF: Holland Frei Cancer Medicine. 9th. Wiley Blackwell; pp. 20082017 | |
Fan X, Quezada SA, Sepulveda MA, Sharma P and Allison JP: Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med. 211:715–725. 2014. View Article : Google Scholar : PubMed/NCBI | |
Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C and Sharma P: CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA. 105:14987–14992. 2008. View Article : Google Scholar | |
Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, et al: Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell. 167:397–404.e9. 2016. View Article : Google Scholar | |
O'Donnell JS, Smyth MJ and Teng MW: Acquired resistance to anti-PD1 therapy: Checkmate to checkpoint blockade? Genome Med. 8:111–116. 2016. View Article : Google Scholar : PubMed/NCBI | |
Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, et al: Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 375:819–829. 2016. View Article : Google Scholar : PubMed/NCBI | |
Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, et al: Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): A multicentre, single-arm, phase 2 study. Lancet Oncol. 18:446–453. 2017. View Article : Google Scholar : PubMed/NCBI | |
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al: Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 372:320–330. 2015. View Article : Google Scholar | |
Meng X, Huang Z, Teng F, Xing L and Yu J: Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev. 41:868–876. 2015. View Article : Google Scholar : PubMed/NCBI | |
Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, et al: VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 23:551–555. 2017. View Article : Google Scholar : PubMed/NCBI | |
Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, et al: Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 7:105012016. View Article : Google Scholar : PubMed/NCBI |